Sarepta (NASDAQ: SRPT) popped as much as 7% on Wednesday to nearly $29 a share. That may seem like a nice boost, but Piper Jaffray has the company going up to somewhere between $60 and $80 in the near term and, staggeringly, suggests the potential for the stock to hit as high as $160 per share. In this video, Motley Fool health-care analyst David Williamson talks about how this relates to the company's tremendous results with its Duchenne muscular dystrophy drug eteplirsen, and how specific catalysts in the weeks and months to come could propel shares higher.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.